Halix Opens New Facility for the Development and Manufacturing of Biopharmaceuticals

The Netherlands: Inauguration Ceremony Halix Opens New Facility for the Development and Manufacturing of Biopharmaceuticals

25.11.2019Editor: Alexander Stark

With an official inauguration ceremony, Halix celebrated the opening of its brand-new 6700 m² cGMP facility at the Leiden Bio Science Park.

Related Companies

Glatt Ingenieurtechnik GmbH

TRM Filter d.o.o.

Frewitt fabrique de machines SA

Halix celebrated the official inauguration ceremony of a new facility for the development and manufacturing of biopharmaceuticals.
(Source: Halix)

Leiden/The Netherlands — Epidemics and pandemics have changed historical life and, as a result of climate change, will transform future life in modern economies. Nowadays, the Chikungunya virus and Zika virus, carried via mosquitoes, are already prevalent in Africa and South America. Halix produces vaccines to prevent spreading those infectious and other viral diseases. The company is also focusing on therapeutic vaccines, specific oncolytic therapeutic vaccines such as to cure dedicated types of cancer.

The opening of a new cGMP facility in Leiden enables Halix to support its clients’ manufacturing of protein-based products, the key technology for future drug production, and virus-based products with cutting-edge technologies. The new building houses GMP production areas for viral and protein products and client-specific technologies, as well as associated laboratory and administration areas.

The new cGMP facility will be starting operational production in Q4-2019.

The new five-level production facility contains a state-of-the-art manufacturing line for viral vaccines and viral vectors, starting soon, with a 250 L bioreactor scale. A separate protein manufacturing area with a capacity up to 1000 L single-use bioreactors is available. Laboratory spaces within the facility enable process development and transfer, analytical development and quality control of biopharmaceuticals.

Ensuring highest quality standards and GMP compliant production, the facility is designed and equipped according to latest biopharmaceutical quality standards. All BSL2 cleanrooms are structured according to the unidirectional process flow of personal and materials and prepared for an upgrade to BSL3, if required. The office spaces, laboratory and cleanroom areas offer up to 70 employees attractive and modern workplaces.

Unfold for details of your consent

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:46255199)

The Netherlands: Inauguration Ceremony Halix Opens New Facility for the Development and Manufacturing of Biopharmaceuticals

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Consent to the use of data for promotional purposes